GlassScriptPhysician profile
Jonathan Alexander Lanham
NPI 1225271745
$7,275.36
in general payments reported to CMS, 2019-2025
38 companies · $1,689 in 2025
The $1,689 reported for 2025 was more than what 81% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $393 · 2020: $576 · 2021: $748 · 2022: $1,031 · 2023: $1,243 · 2024: $1,595 · 2025: $1,689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,528.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,527.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,003.83 | 2019-2025 | |
| Amgen INC. | $842.03 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $685.99 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $580.35 | 2019-2025 | Farxiga, Wainua, Lokelma |
| E.R. Squibb & Sons, L.L.C. | $570.80 | 2020-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $486.51 | 2020-2024 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $419.68 | 2019-2025 | Opsumit, Opsynvi, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $418.86 | 2020-2025 | Jardiance |
| Philips North America LLC | $292.97 | 2022-2025 | Ambulatory Monitoring & Diagnostics Undivided, Ecc Solutions |
| Merck Sharp & Dohme LLC | $208.08 | 2021-2025 | Verquvo, Winrevair, Belsomra |
| United Therapeutics Corporation | $199.96 | 2023-2025 | Tyvaso, Tyvaso |
| Esperion Therapeutics, INC. | $196.73 | 2020-2024 | Nexletol |
| Pfizer INC. | $179.97 | 2019-2025 | |
| Boston Scientific Corporation | $177.01 | 2019-2025 | Watchman Flx, Farapulse |
| Abiomed | $138.32 | 2024-2025 | Impella |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celonova Biosciences, INC. | $134.57 | 2020 | |
| Cvrx, INC. | $83.02 | 2023-2025 | Barostim Neo System |
| Daiichi Sankyo INC. | $73.41 | 2023-2024 | Injectafer |
| Lexicon Pharmaceuticals, INC. | $71.91 | 2023-2024 | Inpefa |
| Novo Nordisk INC | $68.88 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Medtronic Vascular, INC. | $50.12 | 2019 | |
| Alnylam Pharmaceuticals INC. | $42.40 | 2025 | Onpattro |
| Bayer Healthcare Pharmaceuticals INC. | $41.93 | 2024-2025 | |
| Scpharmaceuticals INC. | $40.75 | 2025 | |
| Abbott Laboratories | $38.59 | 2021-2023 | Aveir |
| Cardiovascular Systems INC. | $34.00 | 2021-2023 | Diamondback Coronary |
| Paratek Pharmaceuticals, INC. | $22.47 | 2021 | |
| Medicomp INC | $20.50 | 2022 | |
| Sanofi-Aventis U.S. LLC | $20.44 | 2022 | |
| Cleerly, INC. | $18.21 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Regeneron Healthcare Solutions, INC. | $17.40 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $16.83 | 2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $16.22 | 2024 | Arcalyst |
| Baxter Healthcare | $15.60 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Dexcom, INC. | $13.10 | 2024 | Dexcom G6 Transmitter |
| Edwards Lifesciences Corporation | $12.03 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.89 | 2020 | |
| Bardy Diagnostics, INC. | $10.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Lanham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.